Continual reassessment and related designs in dose‐finding studies

The workshop on the continual reassessment method and related Phase I designs for dose-finding studies was held at Memorial Sloan Kettering Cancer Center in New York on October 2nd, 2009. The workshop was the result of several discussions between Alexia Iasonos and John O'Quigley. These discussions centered around the methodological advancements in Phase I designs with a particular focus on the continual reassessment method (CRM). The participants of the workshop included applied statisticians who have practical experience in using the CRM in clinical trials, an experience gained both in academic and cancer centers, as well as in the pharmaceutical industry in the United States, Japan and Europe. The majority of the participants have participated in Institutional Review Boards and have been involved in discussions with the FDA and European Medicines Agency. One goal of the workshop was to provide a forum to share the lessons learned from finished trials and to discuss the operational and logistical issues, as well as, methodological advancements in adaptive Phase I clinical trial design.

[1]  John O'Quigley,et al.  Retrospective Analysis of Sequential Dose‐Finding Designs , 2005, Biometrics.

[2]  Elizabeth Garrett-Mayer,et al.  The continual reassessment method for dose-finding studies: a tutorial , 2006, Clinical trials.

[3]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[4]  S. Piantadosi,et al.  Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.

[5]  P F Thall,et al.  Accrual strategies for phase I trials with delayed patient outcome. , 1999, Statistics in medicine.

[6]  J Whitehead,et al.  Bayesian decision procedures based on logistic regression models for dose-finding studies. , 1998, Journal of biopharmaceutical statistics.

[7]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[8]  Peter F Thall,et al.  Utility‐Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials , 2010, Biometrics.

[9]  Ying Yuan,et al.  Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .

[10]  C. Ahn,et al.  An evaluation of phase I cancer clinical trial designs , 1998 .

[11]  Mourad Tighiouart,et al.  Translation of innovative designs into phase I trials. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ying Kuen Cheung,et al.  Coherence principles in dose-finding studies , 2005 .

[13]  S. Goodman,et al.  Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.

[14]  B E Storer,et al.  An evaluation of phase I clinical trial designs in the continuous dose–response setting , 2001, Statistics in medicine.

[15]  Ethan Reiner,et al.  Operating characteristics of the standard phase I clinical trial design , 1999 .

[16]  J O'Quigley,et al.  Another look at two phase I clinical trial designs. , 1999, Statistics in medicine.

[17]  John O'Quigley,et al.  Theoretical study of the continual reassessment method , 2006 .

[18]  Alexia Iasonos,et al.  A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in Phase I Dose-Finding Studies , 2008, Clinical trials.

[19]  S Zohar,et al.  Experimental designs for phase I and phase I/II dose-finding studies , 2006, British Journal of Cancer.